SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1093/rheumatology/keab886
- Subjects: PEDIATRIA; DOENÇAS NEONATAIS E ANORMALIDADES; ANTIBIÓTICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Rheumatology
- ISSN: 1462-0324
- Volume/Número/Paginação/Ano: v. 61, n. SI2, suppl.I2, Special Issue, p. SI169-SI174, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SAMPAIO-BARROS, Percival Degrava et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, v. 61, n. SI2, p. SI169-SI174, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab886. Acesso em: 11 fev. 2026. -
APA
Sampaio-Barros, P. D., Medeiros-Ribeiro, A. C., Luppino-Assad, A. P., Miossi, R., Silva, H. C. da, Yuki, E. F. V. N., et al. (2022). SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 61( SI2), SI169-SI174. doi:10.1093/rheumatology/keab886 -
NLM
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1093/rheumatology/keab886 -
Vancouver
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1093/rheumatology/keab886 - Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Lupus nephritis-related issues during COVID-19 pandemic quarantine
- Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus
- High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting
- Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country
- 23-valent polysaccharice pneumococcal vaccine in juvenile idiopathic arthritis patients: anti-tumor necrosis factor therapy role in short and long-term immunogenicity
Informações sobre o DOI: 10.1093/rheumatology/keab886 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
